Viatris Inc Ord Shs SEC Filings

Viatris Inc officer Andrew Enrietti reported multiple equity award transactions. On March 3, 2026, he received a grant of 110,630 Performance Restricted Stock Units (PRSUs) and exercised the same number of PRSUs into common stock at a price of $0.00 per share.

On March 3 and March 4, 2026, restricted stock units and dividend equivalent units previously granted in 2023 and 2024 vested and were converted into common stock at $0.00 per share, while several blocks of common shares were withheld at prices of $14.89 and $14.71 per share to cover tax liabilities. After these transactions, his directly held common stock position was 208,308 shares.

Viatris Inc officer Paul Campbell reported multiple equity compensation events involving restricted stock units, performance RSUs, dividend equivalent units, and common stock. On March 3, 2026, he received 169,718 performance RSUs, which vested the same day and were converted into common shares, along with vested RSUs and related dividend equivalents from prior grants.

Common shares delivered from these vestings were partly withheld to satisfy tax liabilities, including 74,320 shares at $14.8900 per share and other smaller withholdings at similar prices, as noted in the footnotes. After the March 4, 2026 transactions, Campbell directly held 371,353 shares of common stock, plus 318 shares held indirectly through a 401(k) plan.

Viatris Inc. chief executive officer Scott Andrew Smith reported multiple equity award transactions involving restricted stock units, performance restricted stock units, dividend equivalent units, and common stock. On March 3, 2026, he received 1,286,849 Performance Restricted Stock Units as a grant and then exercised the same number of PRSUs into common shares at a price of $0.00 per share.

That same day, he also converted 135,828 restricted stock units and 18,153.1987 dividend equivalent units into common stock, and common shares were disposed of at $14.89 per share to satisfy tax liabilities associated with these vestings, including 506,376 shares withheld. On March 4, 2026, additional RSUs and dividend equivalent units granted on March 4, 2024 converted into common stock, with share withholding transactions at $14.71 per share to cover related tax obligations. After these transactions, Smith continued to hold over one million shares of Viatris common stock directly.

Viatris Inc. filed its annual report outlining a global generics and brands business that generated $14.30 billion in 2025 total revenues while reshaping its portfolio through multiple divestitures and an expanding pipeline of complex and innovative drugs.

The company highlighted five positive Phase 3 data readouts, new launches such as iron sucrose injection in the U.S., and geographic expansion for Inpefa and other products. In 2025 Viatris returned more than $1 billion to shareholders, including about $500 million of share repurchases and $561 million in dividends.

An enterprise-wide strategic review led to a restructuring program with an expected global workforce reduction of up to 10%, projected pre-tax charges of $700–$850 million and targeted annual savings of $600–$700 million once fully implemented. The filing also describes remediation of an FDA warning letter for the Indore, India site and a temporary production halt following a fire at the Nashik, India facility, alongside extensive risk factor disclosures on pricing pressure, regulation, globalization and execution of its strategic plan.

Viatris Inc. reported 2025 total revenues of $14.3B, down 3%, and a U.S. GAAP net loss of $3.5B driven largely by a $2.9B goodwill impairment. Adjusted EBITDA was $4.16B, down 11%, while free cash flow was $1.94B.

The company completed an enterprise-wide strategic review and plans a global workforce reduction of up to 10%, expecting $700M–$850M in pre-tax restructuring charges and potential annual savings of $600M–$700M. For 2026, Viatris guides to revenues of $14.45B–$14.95B, adjusted EBITDA of $4.15B–$4.45B, and adjusted EPS of $2.33–$2.47, and estimates free cash flow excluding transaction- and restructuring-related costs of $1.95B–$2.35B.

Viatris Inc.'s Chief Legal Officer, Matthew Joseph Maletta, filed an initial ownership report showing he beneficially owns 25 shares of Viatris common stock. These shares are held in his name directly, and the filing does not report any new purchase or sale transactions.

Davis Selected Advisers filed an amended ownership report on Viatris Inc., disclosing beneficial ownership of 78,177,984 shares of common stock, representing 6.1% of the outstanding class.

The firm reports sole voting power over 67,210,658 shares and sole dispositive power over all 78,177,984 shares.

Davis Selected Advisers certifies that the Viatris shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the company.

Viatris Inc. reported a leadership change in its top legal role. Chief Legal Officer Brian Roman will step down from that position effective February 9, 2026 and remain with the company until April 1, 2026 to support the transition.

In connection with his departure, he will be eligible for separation payments equal to his base salary plus target bonus and a pro rata 2026 bonus, consistent with benefits for similar executives, and would sign a customary release of claims. Viatris also announced that Matthew Maletta, who previously served as Executive Vice President, Chief Legal Officer and Secretary of Endo, Inc. from 2015 to 2025, will join as Chief Legal Officer on February 9, 2026.

Viatris Inc. (VTRS) reported Q3 2025 results with total revenues of $3,759.9 million (essentially flat year over year) and a net loss of $128.2 million versus net earnings of $94.8 million a year ago. Net sales were $3,747.5 million. Gross profit was $1,371.5 million, down from $1,459.2 million as cost of sales rose. Operating income was $178.8 million, tempered by higher other expense.

Year-to-date, results reflect significant non-cash charges: a goodwill impairment of $2,936.8 million contributed to a YTD net loss of $3,174.8 million on revenues of $10,596.3 million. Operating cash flow was solid at $1,500.1 million. Cash and equivalents were $975.3 million; long‑term debt was $12,487.6 million with the current portion at $1,951.9 million. The company continued returning capital via share repurchases ($415.4 million YTD) and dividends ($423.0 million YTD). Selected products grew, including Lipitor $396.1 million and EpiPen $157.2 million in Q3. Shares outstanding were 1,151,769,872 as of November 3, 2025.